A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease

NCT05842967 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age

NCT03303625 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04732871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208 ·Status: COMPLETED ·Phase: PHASE3

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03596801 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

NCT06593587 ·Status: COMPLETED ·Phase: PHASE3

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

NCT07543380 ·Status: RECRUITING ·Phase: PHASE3

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

NCT00345670 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine

NCT07418229 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection

NCT05070546 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

NCT07128121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

NCT06551181 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

NCT03502707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

NCT04424316 ·Status: COMPLETED ·Phase: PHASE3

A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years

NCT06573281 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT02601612 ·Status: COMPLETED ·Phase: PHASE1

Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years

NCT06216093 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults

NCT02266628 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines

NCT01905215 ·Status: COMPLETED ·Phase: PHASE1

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198 ·Status: COMPLETED ·Phase: PHASE1

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

NCT04138056 ·Status: COMPLETED ·Phase: PHASE2

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

NCT03636906 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

NCT05900154 ·Status: COMPLETED ·Phase: PHASE1